Literature DB >> 28162792

Synthetic Pot: Not Your Grandfather's Marijuana.

Benjamin M Ford1, Sherrica Tai2, William E Fantegrossi1, Paul L Prather3.   

Abstract

In the early 2000s in Europe and shortly thereafter in the USA, it was reported that 'legal' forms of marijuana were being sold under the name K2 and/or Spice. Active ingredients in K2/Spice products were determined to be synthetic cannabinoids (SCBs), producing psychotropic actions via CB1 cannabinoid receptors, similar to those of Δ9-tetrahydrocannabinol (Δ9-THC), the primary active constituent in marijuana. Often abused by adolescents and military personnel to elude detection in drug tests due to their lack of structural similarity to Δ9-THC, SCBs are falsely marketed as safe marijuana substitutes. Instead, SCBs are a highly structural diverse group of compounds, easily synthesized, which produce very dangerous adverse effects occurring by, as of yet, unknown mechanisms. Therefore, available evidence indicates that K2/Spice products are clearly not safe marijuana alternatives.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28162792      PMCID: PMC5329767          DOI: 10.1016/j.tips.2016.12.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  185 in total

1.  Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.

Authors:  Lisa K Brents; Sarah M Zimmerman; Amanda R Saffell; Paul L Prather; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2013-06-25       Impact factor: 4.030

2.  Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice.

Authors:  William S Hyatt; William E Fantegrossi
Journal:  Behav Pharmacol       Date:  2014-06       Impact factor: 2.293

3.  Could spice drugs induce psychosis with abnormal movements similar to catatonia?

Authors:  Gonzalo Haro; Carmen Ripoll; María Ibáñez; Teresa Orengo; Víctor M Liaño; Emilio Meneu; Félix Hernández; Francisco Traver
Journal:  Psychiatry       Date:  2014       Impact factor: 2.458

4.  Aspects of tolerance to and dependence on cannabis.

Authors:  A Wikler
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

5.  A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice.

Authors:  E Valjent; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

6.  Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.

Authors:  P J Little; D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

7.  Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.

Authors:  F Fan; D R Compton; S Ward; L Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

Review 8.  Nephrotoxic effects of designer drugs: synthetic is not better!

Authors:  Randy L Luciano; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2014-03-25       Impact factor: 28.314

9.  College students and use of K2: an emerging drug of abuse in young persons.

Authors:  Xingdi Hu; Brian A Primack; Tracey E Barnett; Robert L Cook
Journal:  Subst Abuse Treat Prev Policy       Date:  2011-07-11

10.  Assessment of the Abuse Liability of Synthetic Cannabinoid Agonists JWH-030, JWH-175, and JWH-176.

Authors:  Reinholdgher Tampus; Seong Shoon Yoon; June Bryan de la Peña; Chrislean Jun Botanas; Hee Jin Kim; Joung-Wook Seo; Eun Ju Jeong; Choon Gon Jang; Jae Hoon Cheong
Journal:  Biomol Ther (Seoul)       Date:  2015-11-01       Impact factor: 4.634

View more
  27 in total

1.  Positive Allosteric Modulation of the 5-HT1A Receptor by Indole-Based Synthetic Cannabinoids Abused by Humans.

Authors:  Hideaki Yano; Pramisha Adhikari; Sett Naing; Alexander F Hoffman; Michael H Baumann; Carl R Lupica; Lei Shi
Journal:  ACS Chem Neurosci       Date:  2020-04-30       Impact factor: 4.418

2.  Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073.

Authors:  Ziva D Cooper; Justin L Poklis; Fei Liu
Journal:  Neuropharmacology       Date:  2017-11-14       Impact factor: 5.250

3.  Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study.

Authors:  Eef L Theunissen; Nadia R P W Hutten; Natasha L Mason; Stefan W Toennes; Kim P C Kuypers; Eliza B de Sousa Fernandes Perna; Johannes G Ramaekers
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

4.  Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.

Authors:  Julie A Marusich; Jenny L Wiley; Timothy W Lefever; Purvi R Patel; Brian F Thomas
Journal:  Neuropharmacology       Date:  2017-11-04       Impact factor: 5.250

5.  Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.

Authors:  Benjamin M Ford; Lirit N Franks; Sherrica Tai; William E Fantegrossi; Edward L Stahl; Michael D Berquist; Christian V Cabanlong; Catheryn D Wilson; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Pharmacol Res       Date:  2017-08-23       Impact factor: 7.658

6.  Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice.

Authors:  Catheryn D Wilson; Sherrica Tai; Laura Ewing; Jasmine Crane; Taylor Lockhart; Ryochi Fujiwara; Anna Radominska-Pandya; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2018-11-12       Impact factor: 4.030

Review 7.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

Review 8.  A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

Authors:  Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Ther       Date:  2019-05-07       Impact factor: 12.310

Review 9.  Cannabinoid exposure during pregnancy and its impact on immune function.

Authors:  Catherine Dong; Jingwen Chen; Amy Harrington; K Yaragudri Vinod; Muralidhar L Hegde; Venkatesh L Hegde
Journal:  Cell Mol Life Sci       Date:  2018-10-29       Impact factor: 9.261

10.  Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity.

Authors:  Anna Pinson; Azure L Yarbrough; John M Bush; Christian V Cabanlong; Amal Shoeib; Bailey K Jackson; Saki Fukuda; Jyoti Gogoi; William E Fantegrossi; Keith McCain; Paul L Prather; Ryoichi Fujiwara; Anna Radominska-Pandya
Journal:  Pharmacol Biochem Behav       Date:  2020-05-13       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.